209 related articles for article (PubMed ID: 37673901)
1. Xanomeline displays concomitant orthosteric and allosteric binding modes at the M
Burger WAC; Pham V; Vuckovic Z; Powers AS; Mobbs JI; Laloudakis Y; Glukhova A; Wootten D; Tobin AB; Sexton PM; Paul SM; Felder CC; Danev R; Dror RO; Christopoulos A; Valant C; Thal DM
Nat Commun; 2023 Sep; 14(1):5440. PubMed ID: 37673901
[TBL] [Abstract][Full Text] [Related]
2. Biased Profile of Xanomeline at the Recombinant Human M
McDonald JK; van der Westhuizen ET; Pham V; Thompson G; Felder CC; Paul SM; Thal DM; Christopoulos A; Valant C
ACS Chem Neurosci; 2022 Apr; 13(8):1206-1218. PubMed ID: 35380782
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological hallmarks of allostery at the M4 muscarinic receptor elucidated through structure and dynamics.
Vuckovic Z; Wang J; Pham V; Mobbs JI; Belousoff MJ; Bhattarai A; Burger WAC; Thompson G; Yeasmin M; Nawaratne V; Leach K; van der Westhuizen ET; Khajehali E; Liang YL; Glukhova A; Wootten D; Lindsley CW; Tobin A; Sexton P; Danev R; Valant C; Miao Y; Christopoulos A; Thal DM
Elife; 2023 May; 12():. PubMed ID: 37248726
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Development of Muscarinic Acetylcholine M
Takai K; Enomoto T
Chem Pharm Bull (Tokyo); 2018; 66(1):37-44. PubMed ID: 29311510
[TBL] [Abstract][Full Text] [Related]
5. Classics in Chemical Neuroscience: Xanomeline.
Bender AM; Jones CK; Lindsley CW
ACS Chem Neurosci; 2017 Mar; 8(3):435-443. PubMed ID: 28141924
[TBL] [Abstract][Full Text] [Related]
6. Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms.
Nawaratne V; Leach K; Felder CC; Sexton PM; Christopoulos A
J Biol Chem; 2010 Jun; 285(25):19012-21. PubMed ID: 20406819
[TBL] [Abstract][Full Text] [Related]
7. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
8. Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor.
Suratman S; Leach K; Sexton P; Felder C; Loiacono R; Christopoulos A
Br J Pharmacol; 2011 Apr; 162(7):1659-70. PubMed ID: 21198541
[TBL] [Abstract][Full Text] [Related]
9. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
Lanzafame AA; Sexton PM; Christopoulos A
Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
[TBL] [Abstract][Full Text] [Related]
10. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
[TBL] [Abstract][Full Text] [Related]
11. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug).
Nawaratne V; Leach K; Suratman N; Loiacono RE; Felder CC; Armbruster BN; Roth BL; Sexton PM; Christopoulos A
Mol Pharmacol; 2008 Oct; 74(4):1119-31. PubMed ID: 18628403
[TBL] [Abstract][Full Text] [Related]
12. Role of Conserved Tyrosine Lid Residues in the Activation of the M
Pham V; Habben Jansen MCC; Thompson G; Heitman LH; Christopoulos A; Thal DM; Valant C
Mol Pharmacol; 2023 Sep; 104(3):92-104. PubMed ID: 37348914
[TBL] [Abstract][Full Text] [Related]
13. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
[TBL] [Abstract][Full Text] [Related]
14. Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor.
De Lorme KC; Sikorski KL; Grant MK; El-Fakahany EE
Neurosci Lett; 2006 Dec; 410(1):11-4. PubMed ID: 17052840
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Leach K; Loiacono RE; Felder CC; McKinzie DL; Mogg A; Shaw DB; Sexton PM; Christopoulos A
Neuropsychopharmacology; 2010 Mar; 35(4):855-69. PubMed ID: 19940843
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand.
Valant C; Gregory KJ; Hall NE; Scammells PJ; Lew MJ; Sexton PM; Christopoulos A
J Biol Chem; 2008 Oct; 283(43):29312-21. PubMed ID: 18723515
[TBL] [Abstract][Full Text] [Related]
17. Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats.
Thomsen M; Fulton BS; Caine SB
Psychopharmacology (Berl); 2014 Feb; 231(3):469-79. PubMed ID: 23995301
[TBL] [Abstract][Full Text] [Related]
18. Identification of a Novel Allosteric Site at the M
Burger WAC; Gentry PR; Berizzi AE; Vuckovic Z; van der Westhuizen ET; Thompson G; Yeasmin M; Lindsley CW; Sexton PM; Langmead CJ; Tobin AB; Christopoulos A; Valant C; Thal DM
ACS Chem Neurosci; 2021 Aug; 12(16):3112-3123. PubMed ID: 34351123
[TBL] [Abstract][Full Text] [Related]
19. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Barak S; Weiner I
Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
